Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Teva
Fish and Richardson
Farmers Insurance
Boehringer Ingelheim
UBS
Fuji
Johnson and Johnson
Moodys

Generated: February 18, 2018

DrugPatentWatch Database Preview

Chiesi Usa Inc Company Profile

« Back to Dashboard

Summary for Chiesi Usa Inc
International Patents:196
US Patents:16
Tradenames:12
Ingredients:6
NDAs:9

Drugs and US Patents for Chiesi Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-005 Nov 7, 2008 RX Yes Yes 9,364,564 ➤ Try a Free Trial Y ➤ Try a Free Trial
Chiesi Usa Inc CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes 7,659,291 ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-002 Jul 31, 2008 RX Yes Yes 7,612,102 ➤ Try a Free Trial Y ➤ Try a Free Trial
Chiesi Usa Inc CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-002 Jul 31, 2008 RX Yes Yes 8,455,524 ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes 9,427,448 ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-001 Feb 21, 1992 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-002 Jul 31, 2008 RX Yes Yes 9,364,564 ➤ Try a Free Trial Y ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes 5,856,346 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Chiesi Usa Inc CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-005 Nov 7, 2008 RX Yes Yes 8,455,524 ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes 9,700,575 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Chiesi Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-002 Feb 21, 1992 5,198,226 ➤ Try a Free Trial
Chiesi Usa Inc ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007 5,422,123 ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 5,739,152 ➤ Try a Free Trial
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 5,164,405 ➤ Try a Free Trial
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 6,114,313 ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 5,739,152 ➤ Try a Free Trial
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-001 Feb 21, 1992 3,985,758 ➤ Try a Free Trial
Chiesi Usa Inc ZYFLO zileuton TABLET;ORAL 020471-001 Dec 9, 1996 4,873,259 ➤ Try a Free Trial
Chiesi Usa Inc ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007 6,183,778 ➤ Try a Free Trial
Chiesi Usa Inc ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007 4,873,259 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for CHIESI USA INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Inhalation Solution 300 mg/4 mL ➤ Subscribe 8/31/2017
➤ Subscribe Injection 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL ➤ Subscribe 6/20/2013
➤ Subscribe Injection 2.5 mg/mL, 10 mL Ampoules ➤ Subscribe 12/27/2006

Non-Orange Book US Patents for Chiesi Usa Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,549,994 Compositions of nicardipine and sulfoalkylated .beta.-cyclodextrin ➤ Try a Free Trial
8,168,598 Optimised formulation of tobramycin for aerosolization ➤ Try a Free Trial
8,716,261 Maintenance of platelet inhibition during antiplatelet therapy ➤ Try a Free Trial
7,659,290 Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions ➤ Try a Free Trial
8,871,736 Maintenance of platelet inhibition during antiplatelet therapy ➤ Try a Free Trial
9,370,586 Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions ➤ Try a Free Trial
9,320,754 Maintenance of platelet inhibition during antiplatelet therapy ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Chiesi Usa Inc Drugs

Supplementary Protection Certificates for Chiesi Usa Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1273292/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
209 Luxembourg ➤ Try a Free Trial PRODUCT NAME: CLEVIDIPINE SOUS TOUTES LES FORMES PROCURANT UNE PROTECTION A PARTIR DU BREVET DE BASE
C0060 France ➤ Try a Free Trial PRODUCT NAME: CANGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,NOTAMMENT UN SEL TETRASODIQUE; REGISTRATION NO/DATE: EU/1/15/994/001 20150323
C0053 France ➤ Try a Free Trial PRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: NL 37621 20120725; FIRST REGISTRATION: GB - PL 16881/0003 20111123
0722 Netherlands ➤ Try a Free Trial PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
2015000021 Germany ➤ Try a Free Trial PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
90008-0 Sweden ➤ Try a Free Trial PRODUCT NAME: CLEVIDIPINE; NAT. REG. NO/DATE: 42321 20120120; FIRST REG.: GB PL 16881/0003 20111123
0726894/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: RACEMISCHES CLEVIDIPINBUTYRAT; REGISTRATION NO/DATE: SWISSMEDIC 60117 11.06.2010
00722 Netherlands ➤ Try a Free Trial PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
2015 00017 Denmark ➤ Try a Free Trial PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Army
Moodys
Cipla
Healthtrust
Daiichi Sankyo
McKinsey
Argus Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot